Clinical trials involving statins, angiotensin II receptor antagonists, beta blockers [31], and angiotensin-converting enzyme inhibitors [32] have shown no significant differences between treatment arms at worst, and only transient protective effects with conflicting results at best, with no reduction in heart failure incidence. The gene discussed is ACE; the disease is heart failure.